Stay updated on MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial
Sign up to get notified when there's something new on the MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial page.

Latest updates to the MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe site revision label was updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check19 days agoChange DetectedThe change appears to be a revision label update from v3.4.0 to v3.4.1; no user-facing content or functionality changes were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page now displays Revision: v3.3.4 instead of Revision: v3.3.3, indicating a minor update with no observable content changes.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded a Locations section with Pennsylvania as a listed site. The HHS Vulnerability Disclosure link and the Pennsylvania Locations entry were removed, and the page revision updated to v3.3.3.SummaryDifference0.2%

- Check91 days agoChange DetectedPublications section wording updated to clarify that publications are provided by the person entering information about the study, and the revision number is changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check99 days agoChange DetectedNotice about government funding and operating status has been removed from the page. All substantive study details (title, eligibility criteria, endpoints, and participation information) remain unchanged.SummaryDifference0.4%

Stay in the know with updates to MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial page.